Literature DB >> 12798424

Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling.

Antony J Workman1, Kathleen A Kane, Julie A Russell, John Norrie, Andrew C Rankin.   

Abstract

OBJECTIVE: Chronic beta-adrenoceptor antagonist (beta-blocker) treatment reduces the incidence of reversion to AF in patients, possibly via an adaptive myocardial response. However, the underlying electrophysiological mechanisms are presently unclear. We aimed to investigate electrophysiological changes in human atrial cells associated with chronic treatment with beta-blockers and other cardiovascular-acting drugs.
METHODS: Myocytes were isolated enzymatically from the right atrial appendage of 40 consenting patients who were in sinus rhythm. The cellular action potential duration (APD), effective refractory period (ERP), L-type Ca(2+) current (I(CaL)), transient (I(TO)) and sustained (I(KSUS)) outward K(+) currents, and input resistance (R(i)) were recorded using the whole cell patch clamp. Drug treatments and clinical characteristics were compared with electrophysiological measurements using simple and multiple regression analyses. P<0.05 was taken as statistically significant.
RESULTS: In atrial cells from patients treated chronically with beta-blockers, the APD(90) and ERP (75 beats/min stimulation) were significantly longer, at 213+/-11 and 233+/-11 ms, respectively (n=15 patients), than in cells from non-beta-blocked patients, at 176+/-12 and 184+/-12 ms (n=11). These cells also displayed a significantly reduced action potential phase 1 velocity (22+/-3 vs. 34+/-3 V/s). Chronic beta-blockade was also associated with a significant reduction in the heart rate (58+/-3 vs. 69+/-5 beats/min) and in the density of I(TO) (8.7+/-1.3 vs. 13.7+/-2.1 pA/pF), an increase in the R(i) (214+/-24 vs. 132+/-14 MOmega), but no significant change in I(CaL) or I(KSUS). The I(TO) blocker 4-aminopyridine largely mimicked the changes in phase 1 and ERP associated with chronic beta-blockade, in cells from non-beta-blocked patients. Chronic treatment of patients with calcium channel blockers or angiotensin converting enzyme inhibitors (n=11-13 patients) was not associated with any significant changes in atrial cell electrophysiology.
CONCLUSION: The observed atrial cellular electrophysiological changes associated with chronic beta-blockade are consistent with a long-term adaptive response, a type of 'pharmacological remodelling', and provide mechanistic evidence supportive of the anti-arrhythmic actions of beta-blockade.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12798424     DOI: 10.1016/s0008-6363(03)00263-3

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  19 in total

1.  Remodelling of human atrial K+ currents but not ion channel expression by chronic β-blockade.

Authors:  Gillian E Marshall; Julie A Russell; James O Tellez; Pardeep S Jhund; Susan Currie; John Dempster; Mark R Boyett; Kathleen A Kane; Andrew C Rankin; Antony J Workman
Journal:  Pflugers Arch       Date:  2011-12-08       Impact factor: 3.657

2.  Effects of low-level carotid baroreflex stimulation on atrial electrophysiology.

Authors:  Mingyan Dai; Mingwei Bao; Jiafen Liao; Lilei Yu; Yanhong Tang; He Huang; Xi Wang; Congxin Huang
Journal:  J Interv Card Electrophysiol       Date:  2015-04-15       Impact factor: 1.900

3.  Transient outward K+ current reduction prolongs action potentials and promotes afterdepolarisations: a dynamic-clamp study in human and rabbit cardiac atrial myocytes.

Authors:  A J Workman; G E Marshall; A C Rankin; G L Smith; J Dempster
Journal:  J Physiol       Date:  2012-06-25       Impact factor: 5.182

4.  Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation.

Authors:  Sandeep V Pandit; Omer Berenfeld; Justus M B Anumonwo; Roman M Zaritski; James Kneller; Stanley Nattel; José Jalife
Journal:  Biophys J       Date:  2005-03-25       Impact factor: 4.033

5.  Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism.

Authors:  Ryan G Aleong; William H Sauer; Gordon Davis; Guinevere A Murphy; J David Port; Inder S Anand; Mona Fiuzat; Christopher M O'Connor; William T Abraham; Stephen B Liggett; Michael R Bristow
Journal:  JACC Heart Fail       Date:  2013-08       Impact factor: 12.035

6.  Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study.

Authors:  V Simopoulos; G Tagarakis; A Hatziefthimiou; I Skoularigis; F Triposkiadis; V Trantou; N Tsilimingas; I Aidonidis
Journal:  Clin Res Cardiol       Date:  2014-08-19       Impact factor: 5.460

7.  Post-operative atrial fibrillation is influenced by beta-blocker therapy but not by pre-operative atrial cellular electrophysiology.

Authors:  Antony J Workman; Davide Pau; Calum J Redpath; Gillian E Marshall; Julie A Russell; Kathleen A Kane; John Norrie; Andrew C Rankin
Journal:  J Cardiovasc Electrophysiol       Date:  2006-11

Review 8.  Cardiac adrenergic control and atrial fibrillation.

Authors:  Antony J Workman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-04       Impact factor: 3.000

9.  Atrial cellular electrophysiological changes in patients with ventricular dysfunction may predispose to AF.

Authors:  Antony J Workman; Davide Pau; Calum J Redpath; Gillian E Marshall; Julie A Russell; John Norrie; Kathleen A Kane; Andrew C Rankin
Journal:  Heart Rhythm       Date:  2008-12-31       Impact factor: 6.343

10.  Cellular bases for human atrial fibrillation.

Authors:  Antony J Workman; Kathleen A Kane; Andrew C Rankin
Journal:  Heart Rhythm       Date:  2008-01-17       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.